A Digital Antimicrobial Stewardship Smartphone Application to Combat AMR: the AB-assistant
NCT ID: NCT03793946
Last Updated: 2020-08-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
1080 participants
INTERVENTIONAL
2020-09-30
2022-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
INSPIRE Trial for Abdominal Infections
NCT05423743
Impact of Prescription Quality, Infection Control and Antimicrobial Stewardship on Gut Microbiota Domination by Healthcare-Associated Pathogens
NCT03765528
Antibiotic Treatment Versus no Therapy in Kidney Transplant Recipients With Asymptomatic Bacteriuria
NCT01771432
Antibiotic Stewardship and Infection Control in Patients at High Risk of Developing Infection by Clostridium Difficile, Vancomycin-Resistant Enterococci or Multi-Resistant Gram-Negatives
NCT03250104
Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae
NCT02795949
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objective: The study aims to adapt and evaluate the "AB-assistant", a smartphone based digital stewardship application that is customizable to local guidelines by local antibiotic stewards and therefore has the potential to be used worldwide, including in low- and middle-income countries.
Study design: The existing North American Spectrum app (SpectrumMD; Canada) will be adjusted and translated for the European market. During a usability study physicians will use the app for two weeks followed by individual interviews to determine facilitators and barriers of app use. Based on the results of these interviews the app will be adjusted if necessary. After adaptation and usability testing, thereafter the AB-assistant app will be evaluated in an international, multicentre, randomized clinical trial involving centres in 3 countries in different settings with appropriate antimicrobial use as a primary outcome. In a stepped wedge cluster randomized trial, wards will be randomised after stratification for specialty. At baseline a 2-week measurement period will be done, followed by the introduction of the intervention to 6 wards (in 3 hospitals) with a 4-week interval with 6 inclusion periods. This cycle will be repeated with the inclusion of all new intervention wards. We include the 36 wards in total during the 6 inclusion phases and at the end of the inclusion time we allow use of the app by everyone, also wards not included in the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AB-assistant
Use of the AB-assistant app by physicians in intervention wards.
AB-assistant
The AB-assistant is an antimicrobial stewardship smartphone application that offers local antimicrobial guidelines to physicians currently assessed per website or paper/digital booklet.
Standard antimicrobial stewardship
Physicians on these wards will use conventional ways to assess local guidelines to prescribe antimicrobials.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AB-assistant
The AB-assistant is an antimicrobial stewardship smartphone application that offers local antimicrobial guidelines to physicians currently assessed per website or paper/digital booklet.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
• Medical and surgical wards.
Physician level:
• All physicians involved in antibiotic prescribing decisions in the participating wards.
Patient level:
• All patients hospitalized in the participating wards \>= 18 years of age to whom systemic antimicrobials are prescribed.
Exclusion Criteria
* Outpatient clinics
* Psychiatry wards
* ICU
Physician level:
• None
Patient level:
• None
Treatment level:
• Surgical and medical prophylaxis.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Erasmus Medical Center
OTHER
University Hospital, Geneva
OTHER
Uppsala University Hospital
OTHER
University of Calgary Cumming School of Medicine
UNKNOWN
Annelies Verbon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Annelies Verbon
Prof. dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
B D Huttner, MD, MS
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Geneva
T Tängdén, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Uppsala University
John Conly, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
University of Calgary Cumming School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Calgary Cumming School of Medicine and Alberta Health Services, Department of Medicine
Calgary, Alberta, Canada
Erasmus Medical Center
Rotterdam, South Holland, Netherlands
Uppsala University, Dept of Medical Sciences
Uppsala, , Sweden
Geneva University Hospitals
Geneva, Canton of Geneva, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Helou RI, Catho G, Faxen L, Hulscher M, Teerenstra S, Conly J, Huttner BD, Tangden T, Verbon A. Impact of a smartphone application for appropriate antibiotic prescribing at three tertiary hospitals: an international, multicentre stepped-wedge cluster randomized trial. Clin Microbiol Infect. 2025 Jul;31(7):1172-1179. doi: 10.1016/j.cmi.2025.02.026. Epub 2025 Mar 1.
Helou RI, Catho G, Peyravi Latif A, Mouton J, Hulscher M, Teerenstra S, Conly J, Huttner BD, Tangden T, Verbon A. Study protocol for an international, multicentre stepped-wedge cluster randomised trial to evaluate the impact of a digital antimicrobial stewardship smartphone application. BMJ Open. 2020 Jun 4;10(6):e033640. doi: 10.1136/bmjopen-2019-033640.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZonMw_549003001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.